Acadia Pharmaceuticals (ACAD) Receivables (2016 - 2026)

Acadia Pharmaceuticals has reported Receivables for 11 years, with the latest figure at $166.3 million in Q2 2026.

• On a quarterly basis, Receivables rose 38.97% year-over-year to $166.3 million in Q2 2026; TTM through Jun 2026 was $166.3 million, a 38.97% increase from a year earlier, with the FY2025 full-year figure at $148.2 million, up 41.58% from the prior year.
• Receivables was $166.3 million for Q2 2026 at Acadia Pharmaceuticals, up from $148.4 million in the prior quarter.
• The five-year high for Receivables was $166.3 million in Q2 2026, with the low at $56.1 million in Q3 2022.
• Average Receivables over 5 years is $103.6 million, with a median of $103.5 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: Receivables decreased 8.97% in 2022, then jumped 68.4% in 2023.
• Over 5 years, Receivables stood at $63.1 million in 2022, then surged by 62.25% to $102.4 million in 2023, then rose by 2.29% to $104.7 million in 2024, then soared by 41.58% to $148.2 million in 2025, then rose by 12.21% to $166.3 million in 2026.
• The last three Receivables figures came in at $166.3 million (Q2 2026), $148.4 million (Q1 2026), and $148.2 million (Q4 2025), per Business Quant data.